Premier Health Center, PLLC

Premier Health Center, PLLC was paid $3.47M by Medicaid between Jan 2018 and Dec 2024, across 33 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 36% of everything it billed.

Compared with peers

Next to other Internal Medicine Physician providers in North Carolina

Rank by total paid#16 of 616

Median peer was paid$74K

This provider vs. median47×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	10,333	$436K
2019	9,274	$553K
2020	6,788	$473K
2021	11,729	$560K
2022	13,548	$508K
2023	16,521	$464K
2024incomplete	25,090	$477K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	36%	9,806	5,088	$1.24M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	24%	13,073	6,583	$824K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	20%	15,553	6,668	$698K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	11%	7,063	4,585	$367K
99199	Unlisted special service, procedure or report	7.1%	37,680	22,061	$247K
99051		<1%	1,293	942	$21K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	<1%	84	67	$15K
99406		<1%	1,377	786	$14K
90674		<1%	684	366	$7K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	<1%	71	52	$6K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	397	351	$4K
96156		<1%	67	63	$4K

21 more codes

82947		<1%	1,669	$3K
96127		<1%	1,288	$3K
99395	Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years	<1%	39	$3K
99396	Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years	<1%	34	$3K
99308	Subsequent nursing facility care, per day, straightforward	<1%	334	$2K
36415	Collection of venous blood by venipuncture	<1%	1,564	$2K
99050		<1%	79	$1K
99401		<1%	91	$1K
99408		<1%	76	$1K
99490	Ccm add 20min	<1%	124	$394.10
83036	Hemoglobin; glycosylated (A1C)	<1%	71	$191.52
90653		<1%	27	$48.75
90661		<1%	18	$32.65
81001		<1%	19	$13.34
90694		0%	15	$0.00
G0447	Face-to-face behavioral counseling for obesity, 15 minutes	0%	82	$0.00
G0008	Administration of influenza virus vaccine	0%	123	$0.00
G0443	Brief face-to-face behavioral counseling for alcohol misuse, 15 minutes	0%	173	$0.00
G0442	Annual alcohol misuse screening, 5 to 15 minutes	0%	84	$0.00
G0446	Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes	0%	128	$0.00
G0444	Annual depression screening, 5 to 15 minutes	0%	97	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialAKHTAR, AFAQUE (PHYSICIAN/PARTNER)